A 2-drug combination of direct-acting antivirals developed by AbbVie achieved sustained virological response in 95% of previously untreated patients with genotype 1b hepatitis C infection after 12 weeks of treatment, without the need for pegylated interferon or ribavirin, Eric Lawitz from the Texas Liver Institute reported Sunday at the 64th AASLD ... (more)
http://www.hivandhepatitis.com/hcv-treatment/experimental-hcv-drugs/4390-aasld-2013-abbvies-dual-interferon-free-combination-cures-genotype-1b-hepatitis-c-in-95
http://www.hivandhepatitis.com/hcv-treatment/experimental-hcv-drugs/4390-aasld-2013-abbvies-dual-interferon-free-combination-cures-genotype-1b-hepatitis-c-in-95
No comments:
Post a Comment